Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells

Cell Biology International

Volumn 33, Issue 2, 2009, Pages 239-246

  Karabulut, B ^a   Erten, C ^a   Gul, M K ^a   Cengiz, E ^a   Karaca, B ^a   Kucukzeybek, Y ^a   Gorumlu, G ^a   Atmaca, H ^b   Uzunoglu, S ^b   Sanli, U A ^a   Baran, Y ^c   Uslu, R ^a  

^a Tulay Aktas Oncology Hospital   (Turkey)

^b Faculty of Science and Arts   (Turkey)

^c IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

Author keywords

Bcl 2; Docetaxel; DU 145; PC 3; Prostate cancer; Zoledronic acid

Indexed keywords

DOCETAXEL; HORMONE; PROTEIN BCL 2; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL STRAIN; DOWN REGULATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER;

ANDROGENS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; DIPHOSPHONATES; DNA FRAGMENTATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; IMIDAZOLES; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS;

EID: 58749100624     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2008.11.011     Document Type: Article

References (17)

1. Berthold D.R., Pond G.R., Soban F., De W.R., Eisenberger M., and Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26 (2008) 242-245
2. Caraglia M., Marra M., Leonetti C., Meo G., D'alessandro A.M., Baldi A., et al. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol 211 (2007) 533-543
3. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
4. Corey E., Brown L.G., Quinn J.E., Poot M., Roudier M.P., Higano C.S., et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9 (2003) 295-306
5. Dumon J.C., Journe F., Kheddoumi N., Lagneaux L., and Body J.J. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 45 (2004) 521-528
6. Gligorov J., and Lotz J.P. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 2 Suppl. 9 (2004) 3-8
7. Haldar S., Basu A., and Croce C.M. Bcl2 is the guardian of microtubule integrity. Cancer Res 57 (1997) 229-233
8. Hanauske A.R., Degen D., Hilsenbeck S.G., Bi{dotless}ssery M.C., and Von Hoff D.D. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3 (1992) 121-124
9. Huang J.M., Lin T.Y., Chang D., Lin S.L., and Ying S.Y. Truncated Bcl-2, a potential pre-metastatic marker in prostate cancer. Biochem Biophys Res Commun 306 (2003) 912-917
10. Lee M.V., Fong E.M., Si{dotless}nger F.R., and Guenette R.S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61 (2001) 2602-2608
11. Lin Y., Fukuchi J., Hiipakka R.A., Kokontis J.M., and Xiang J. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Res 17 (2007) 531-536
12. Oades G.M., Senaratne S.G., Clarke I.A., Kirby R.S., and Colston K.W. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170 (2003) 246-252
13. Rothermund C.A., Kondrikov D., Lin M.F., and Vishwanatha J.K. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer. Prostate Cancer Prostatic Dis 5 (2002) 236-245
14. Saad F. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 1 (2002) 145-152
15. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
16. Yoshino T., Shiina H., Urakami S., Kikuno N., Yoneda T., Shigeno K., et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12 (2006) 6116-6124
17. Zhao Z.G., Ma Q.Z., and Xu C.X. Abrogation of heat-shock protein (HSP)70 expression induced cell growth inhibition and apoptosis in human androgen-independent prostate cancer cell line PC-3m. Asian J Androl 6 (2004) 319-324